Sponsored by
Great news! This brings the vaccine closer to approval. Early reports showed over a 6 month improvement in survival, which is significant and 23% of patients had tumor reductions. Fast track designation and orphan designation mean the FDA has looked at the data and shows an interest in speeding it up.